Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP270380.RAXnQidLdng-rwU6G9HtSUfXksZL67HOY0QRpc7_8OYhU130_assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP270380.RAXnQidLdng-rwU6G9HtSUfXksZL67HOY0QRpc7_8OYhU130_provenance.
• NP190437.RAaa7iuJSuYQXkyqUd8v3FQjn-xr2TaYvQeMlZDMQP0zk130_assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP190437.RAaa7iuJSuYQXkyqUd8v3FQjn-xr2TaYvQeMlZDMQP0zk130_provenance.
• NP385179.RAbOk6TJNAl3czLaXFSMyISzmL6u84abU1VcvuJzfQ5OM130_assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP385179.RAbOk6TJNAl3czLaXFSMyISzmL6u84abU1VcvuJzfQ5OM130_provenance.
• NP574892.RAgaAkNru13u3Om_pN7qzQXU6RsOtZbUaqoN0_PyqqQf4130_assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP574892.RAgaAkNru13u3Om_pN7qzQXU6RsOtZbUaqoN0_PyqqQf4130_provenance.
• NP832909.RAaILGdYZ7OjI2bn3IraT-U6xPORlDUzJ_xsIx2Ji3zls130_assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP832909.RAaILGdYZ7OjI2bn3IraT-U6xPORlDUzJ_xsIx2Ji3zls130_provenance.
• assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP697073.RAUxKHcO8YASn9ti4y1j6pDGWWyaOsl66HHAupt3j1ty0130_assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697073.RAUxKHcO8YASn9ti4y1j6pDGWWyaOsl66HHAupt3j1ty0130_provenance.
• NP697076.RAYVI7FhcLkRJBy0s7O5yuxiraU9e-WxWEzlLQ6-vyypA130_assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697076.RAYVI7FhcLkRJBy0s7O5yuxiraU9e-WxWEzlLQ6-vyypA130_provenance.
• assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP697075.RAGgnOi8XHuX-yroY5XYPMXZnjCYde1f-ym1W6KlBLoi0130_assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697075.RAGgnOi8XHuX-yroY5XYPMXZnjCYde1f-ym1W6KlBLoi0130_provenance.
• NP970673.RA4WjQv086kMvP0h9t5LhCyjibrs9n_d7cvMNe1a-KXN4130_assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP970673.RA4WjQv086kMvP0h9t5LhCyjibrs9n_d7cvMNe1a-KXN4130_provenance.
• NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_provenance.
• NP889920.RA7gqrb044YIuLaXjjSgWYZSjcMv65nGnL01ekwY5nCe0130_assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP889920.RA7gqrb044YIuLaXjjSgWYZSjcMv65nGnL01ekwY5nCe0130_provenance.
• NP697074.RA8OBseiXnLJF8XEz9Gx7FevSD4j-TwLJ7xccn5JrOihs130_assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697074.RA8OBseiXnLJF8XEz9Gx7FevSD4j-TwLJ7xccn5JrOihs130_provenance.